30 closest matches · ranked by relevance
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
Hepatic Veno-Occlusive Disease
Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy — 49.9 Percentage of participants alive
Veno-occlusive Disease
Primary: Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC) — 66.8…
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
Sickle Cell Disease · Sickle Cell Crisis
Primary: Rate of Hospital Admission — 63; 55 percentage of participants
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
Chronic Venous Disorder · Venous Outflow Obstruction · Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Primary: Number of Participants With Major Adverse Events (MAE) — 0; 0; 0; 0 Participants
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
Healthy Volunteers · Endotoxemia
Primary: Prothrombin Fragments f1+2 — 31.1; 34.08; 27.41; 36.02 fold-change*h — p=0.408
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Primary: Number of Participants With 30-day Freedom From Major Adverse Events — 232 Participants — p=<0.0001
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
Liver Failure
Primary: Central Venous Pressure (CVP) — 11.7 mmHg
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Pain Score — 5.7 score on a scale
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.9; 92.0; 100.0; 93.8 percentage of participants
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Venous Thromboembolism (VTE) · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056
Anemia
Primary: Maximum Observed Serum Concentration (Cmax) — 8545.33 ug/dL
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Niemann-Pick Disease, Type C
Primary: Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5α-cholanic Acid-3β, 5α, 6β-triol N-(Carboxymethyl)-Amide — 32.6; 87.9 ng/ml
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
Sickle Cell Disease
Primary: Mean Change From Baseline in Haemolysis Marker (Indirect Bilirubin) — 24.0; 56.4; 44.0; 31.2 micromoles per liter (umol/L)
Congenital Heart Disease
Primary: Pulmonary Blood Flow as Determined by MRI Velocity Encoding at 3-6 Months — 3.3; 4.4 L/min — p=0.03
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001